Amicus Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amicus Therapeutics, Inc.
Although Nexviadyme has been approved, the French group is still unhappy about the EMA's view that the Pompe disease therapy should not be classified as a new active substance.
Michael Parini talks to Scrip about how a new focus at the company can help it prove the value of its AAV-based gene therapy platform.
Public Company Edition: Only nine drug developers went public in the US, raising $807m in the first quarter, versus 32 IPOs raising $5.2bn in Q1 of last year. Also, MoonLake closed its SPAC merger, Sanofi priced €650m in sustainability-linked bonds in €1.5bn note sale, and Kaleido will cease operations.
US FDA currently reports about two dozen Accelerated Approval having ‘delays’ in the confirmatory trials. COVID is one factor in some – and the agency also appears to be clearing out some of the others.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Callidus Biopharma
- MiaMed, Inc.
- Scioderm, Inc.